TY - JOUR
T1 - Performance evaluation of a multiplex assay for future use in biomarker discovery efforts to predict body composition
AU - Bea, Jennifer W.
AU - Wright, Nicole C.
AU - Thompson, Patricia
AU - Hu, Chengcheng
AU - Guerra, Stefano
AU - Chen, Zhao
N1 - Funding Information:
We thank the participants and staff of the Women’s Breast and Bone Density Study, Julie Buckmeier, and Leslie Arendell. Support for The WBBD study was provided by the Susan G. Komen Foundation, biomarker assessment by the National Institute on Aging (R01AG027373-01A2), and Dr. Bea by the National Cancer Institute (R25T, CA-78447). Publication of these results will not benefit the supporters.
PY - 2011/5/1
Y1 - 2011/5/1
N2 - Background: Interest in biomarker patterns and disease has led to the development of immunoassays that evaluate multiple analytes in parallel while using little sample. However, there are no current standards for multiplex configuration, validation, and quality. Thus, validation by platform, population, and question of interest is recommended. We sought to determine the best blood fraction for multiplex evaluation of circulating biomarkers in post-menopausal women, and to explore body composition phenotype discrimination by biomarkers. Methods: Archived serum and plasma samples from a sample of healthy post-menopausal women with the highest (n=9) and lowest (n=11) percent lean mass, as determined by dual-energy X-ray absorptiometry, were used to measure 90 analytes using bead-based, suspension multiplex assays. Replicates of serum and plasma were analyzed in a random selection of four of these individuals. Results: Ninety percent of the analytes were detectable for ≥50% of samples; when limited to these well detected analytes, mean replicate correlations for serum and plasma were 0.87 and 0.85, respectively. Serum had lower error rates discriminating phenotypes; seven serum vs. two plasma analytes discriminated extreme body phenotypes. Conclusions: Serum and plasma performed similarly for the majority of the analytes. Serum showed a slight advantage in predicting extreme body composition phenotypes in postmenopausal women using parallel evaluation of analytes.
AB - Background: Interest in biomarker patterns and disease has led to the development of immunoassays that evaluate multiple analytes in parallel while using little sample. However, there are no current standards for multiplex configuration, validation, and quality. Thus, validation by platform, population, and question of interest is recommended. We sought to determine the best blood fraction for multiplex evaluation of circulating biomarkers in post-menopausal women, and to explore body composition phenotype discrimination by biomarkers. Methods: Archived serum and plasma samples from a sample of healthy post-menopausal women with the highest (n=9) and lowest (n=11) percent lean mass, as determined by dual-energy X-ray absorptiometry, were used to measure 90 analytes using bead-based, suspension multiplex assays. Replicates of serum and plasma were analyzed in a random selection of four of these individuals. Results: Ninety percent of the analytes were detectable for ≥50% of samples; when limited to these well detected analytes, mean replicate correlations for serum and plasma were 0.87 and 0.85, respectively. Serum had lower error rates discriminating phenotypes; seven serum vs. two plasma analytes discriminated extreme body phenotypes. Conclusions: Serum and plasma performed similarly for the majority of the analytes. Serum showed a slight advantage in predicting extreme body composition phenotypes in postmenopausal women using parallel evaluation of analytes.
KW - biomarkers
KW - lean mass
KW - multi-analyte
KW - multiplex
KW - phenotype discrimination
UR - http://www.scopus.com/inward/record.url?scp=79954465768&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=79954465768&partnerID=8YFLogxK
U2 - 10.1515/CCLM.2011.122
DO - 10.1515/CCLM.2011.122
M3 - Article
C2 - 21361852
AN - SCOPUS:79954465768
VL - 49
SP - 817
EP - 824
JO - Zeitschrift fur klinische Chemie und klinische Biochemie
JF - Zeitschrift fur klinische Chemie und klinische Biochemie
SN - 1434-6621
IS - 5
ER -